Gemcitabine and carboplatin in the treatment of transitional cell carcinoma of the urothelium: a single centre experience and review of the literature

HUDSON E. & H LESTER J.F. (2010) European Journal of Cancer Care 19 , 324–328
 Gemcitabine and carboplatin in the treatment of transitional cell carcinoma of the urothelium: a single centre experience and review of the literature The objectives of this study are to evaluate patient outcomes in clinical practice using gemcitabine and carboplatin (GCarbo) as first‐line treatment in metastatic transitional cell carcinoma (TCC) of the urothelium, and to review the published evidence on the use of GCarbo in this setting. From July 2003, all cases of metastatic TCC of the urothelium referred to a single consultant were treated using 3‐weekly gemcitabine 1200 mg/m 2 i.v. days 1 and 8 plus carboplatin AUC 5–6 i.v. day 1 to a maximum of six cycles. Fifteen patients (median age 67 years) were treated. Grade 3 or 4 toxicity included neutropenia (47%), anaemia (27%) and thrombocytopenia (20%). No patients required admission for neutropenic pyrexia/sepsis, and there were no treatment‐related deaths. The overall response rate was 67%. The median survival was 9 months (95% CI 7.4–10.6), and 1‐year survival 42%. Gemcitabine and carboplatin is well tolerated, and has activity as first‐line treatment in metastatic TCC of the urothelium. However, there is now evidence suggesting that gemcitabine and cisplatin may be more efficacious, and until the appropriate randomized phase 3 trials have been carried out, gemcitabine and cisplatin should probably remain the preferred first‐line therapy. Gemcitabine and carboplatin is an effective alternative in those patients not deemed fit enough for cisplatin.